60 Degrees Pharmaceuticals, Inc.
SXTPNASDAQHealthcare● Active
$1.43
+$0.01(+0.70%)
Market Cap$1153367
P/E Ratio—
52W High$12.96
52W Low$1.29
60 Degrees Pharmaceuticals, Inc. (SXTP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SXTP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$1.28
Est. -$0.76 · -68.4%
Revenue
$0.00B
Est. $0.00B · -47.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
SXTP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.74 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.76 | -$1.28 | -68.4% | $0.00B | $0.00B | -47.1% |
| ▲ Q1 FY2026 | Mar 26, 2026 | -$2.28 | -$1.69 | +25.9% | $0.00B | $0.00B | -3.1% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -$1.84 | -$2.64 | -43.5% | $0.00B | $0.00B | +118.8% |
| — Q3 FY2025 | Aug 13, 2025 | -$1.24 | -$1.25 | -0.8% | $0.00B | $0.00B | -32.7% |
| ▼ Q2 FY2025 | May 15, 2025 | -$1.31 | -$1.56 | -19.1% | $0.00B | $0.00B | -45.5% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -$4.01 | -$14.20 | -254.1% | $0.00B | $0.00B | +4.6% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$3.00 | -$4.65 | -55.0% | $0.00B | $0.00B | -45.9% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.74
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$1.28
EPS Est.
-$0.76
EPS Surpr.
-68.4%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Beat
EPS Actual
-$1.69
EPS Est.
-$2.28
EPS Surpr.
+25.9%
Revenue
$0.00B
Q4 FY2025
Nov 13, 2025Miss
EPS Actual
-$2.64
EPS Est.
-$1.84
EPS Surpr.
-43.5%
Revenue
$0.00B
Q3 FY2025
Aug 13, 2025
EPS Actual
-$1.25
EPS Est.
-$1.24
EPS Surpr.
-0.8%
Revenue
$0.00B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$1.56
EPS Est.
-$1.31
EPS Surpr.
-19.1%
Revenue
$0.00B
Q1 FY2025
Mar 27, 2025Miss
EPS Actual
-$14.20
EPS Est.
-$4.01
EPS Surpr.
-254.1%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$4.65
EPS Est.
-$3.00
EPS Surpr.
-55.0%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.02 | $-0.89 | $-0.75 | 1 |
| Q3 FY2027 | $-1.04 | $-0.91 | $-0.76 | 1 |
| Q2 FY2027 | $-1.01 | $-0.88 | $-0.74 | 1 |
| Q1 FY2027 | $-1.03 | $-0.90 | $-0.75 | 1 |
| Q4 FY2026 | $-0.99 | $-0.86 | $-0.72 | 1 |
| Q3 FY2026 | $-0.84 | $-0.74 | $-0.64 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 15, 2026 | -68.4% | $1.46 | $1.39 | -4.79% |
| ▲ Q1 FY2026 | Mar 26, 2026 | +25.9% | $1.55 | $1.49 | -3.87% |
| ▼ Q4 FY2025 | Nov 13, 2025 | -43.5% | $4.92 | $4.68 | -4.88% |
| ▲ Q3 FY2025 | Aug 13, 2025 | -0.8% | $5.40 | $5.40 | +0.00% |
| ▼ Q2 FY2025 | May 15, 2025 | -19.1% | $9.00 | $8.60 | -4.44% |
| ▼ Q1 FY2025 | Mar 27, 2025 | -254.1% | $7.52 | $7.28 | -3.19% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -55.0% | $19.60 | $19.00 | -3.06% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -6.8% | $27.00 | $26.60 | -1.48% |
Q2 FY2026-4.79%
Report Date
May 15, 2026
EPS Beat/Miss
-68.4%
Price Before
$1.46
Price After
$1.39
Q1 FY2026-3.87%
Report Date
Mar 26, 2026
EPS Beat/Miss
+25.9%
Price Before
$1.55
Price After
$1.49
Q4 FY2025-4.88%
Report Date
Nov 13, 2025
EPS Beat/Miss
-43.5%
Price Before
$4.92
Price After
$4.68
Q3 FY2025+0.00%
Report Date
Aug 13, 2025
EPS Beat/Miss
-0.8%
Price Before
$5.40
Price After
$5.40
Q2 FY2025-4.44%
Report Date
May 15, 2025
EPS Beat/Miss
-19.1%
Price Before
$9.00
Price After
$8.60
Q1 FY2025-3.19%
Report Date
Mar 27, 2025
EPS Beat/Miss
-254.1%
Price Before
$7.52
Price After
$7.28
Q4 FY2024-3.06%
Report Date
Nov 14, 2024
EPS Beat/Miss
-55.0%
Price Before
$19.60
Price After
$19.00
Q3 FY2024-1.48%
Report Date
Aug 14, 2024
EPS Beat/Miss
-6.8%
Price Before
$27.00
Price After
$26.60
Avg Beat Reaction-1.94%
Avg Miss Reaction-3.64%
Beat Rate2 / 8 quarters
Largest Move-4.88% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SXTP ends December
60 Degrees Pharmaceuticals, Inc. (SXTP) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-1.28 — missing the analyst consensus of $-0.76 by -68.4%. The next SXTP earnings date is expected around September 1, 2026.
Each quarter, investors track SXTP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SXTP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SXTP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SXTP earnings · 5 questions60 Degrees Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. SXTP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SXTP historically reports after market close (AMC).
SXTP earnings datewhen is SXTP earningsSXTP next earnings datewhen does SXTP report earningsSXTP earnings calendar
▸ Source: FMP · 60 Degrees Pharmaceuticals, Inc. SEC filings · US GAAP · 60 Degrees Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026